- Home
- AUTL vs MAX Comparison
AUTL vs MAX Comparison
Compare AUTL & MAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUTL | MAX |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.2M | 516.4M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AUTL | MAX |
|---|---|---|
| Price | $1.64 | $8.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $8.50 | ★ $12.70 |
| AVG Volume (30 Days) | ★ 1.6M | 592.8K |
| Earning Date | 05-14-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.81 |
| EPS | N/A | ★ 0.21 |
| Revenue | $10,120,000.00 | ★ $1,113,600,000.00 |
| Revenue This Year | $80.32 | $13.42 |
| Revenue Next Year | $53.96 | $8.16 |
| P/E Ratio | ★ N/A | $39.83 |
| Revenue Growth | ★ 496.00 | 28.78 |
| 52 Week Low | $1.18 | $7.09 |
| 52 Week High | $2.70 | $13.92 |
Technical Indicators
Market Signals| Indicator | AUTL | MAX |
|---|---|---|
| Relative Strength Index (RSI) | 52.86 | 40.18 |
| Support Level | $1.27 | $7.09 |
| Resistance Level | $1.73 | $10.10 |
| Average True Range (ATR) | 0.14 | 0.44 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 40.91 | 26.90 |
Price Performance
Historical ComparisonAbout AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that enables insurance carriers and distributors to target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It serves as a customer acquisition channel in property and casualty insurance, health insurance, and life insurance. The company operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.